Nonmuscle Invasive Bladder Cancer research hub

A Phase 3, Single-arm, Multicenter Study to Evaluate the Efficacy and Safety of UGN-103, a Novel Formulation of UGN-102, for the Treatment of Patients With Low Grade (LG) Nonmuscle Invasive Bladder Cancer (NMIBC) at Intermediate Risk (IR) of Recurrence (UTOPIA)

This phase 3 study tests a new treatment called UGN-103 for non-muscle invasive bladder cancer. UGN-103 is a medicine placed directly into the bladder to help clear early-stage cancer cells. Researchers want to see how well it works, how safe it is, and if it can reduce the need for surgery.